EU negotiators have reached an agreement to strengthen the supply chains for essential medicines, addressing recent shortages in the bloc. The new rules will facilitate public funding for the production of vital medicines and prioritise European-made drugs in public procurement processes.
This initiative responds to vulnerabilities exposed during the pandemic, where reliance on a limited number of countries for active ingredients led to supply disruptions. Currently, 80% to 90% of medicines used in Europe are sourced from Asia, primarily China, highlighting the need for a more resilient supply chain.
For UK residents, these changes could mean more reliable access to essential medicines, as the EU’s efforts may influence similar policies in the UK. If the UK aligns with these regulations, it could enhance local production and reduce dependency on foreign suppliers, potentially stabilising prices and availability.
Looking ahead, watch for the approval of these rules by EU member states and the European Parliament, as well as any corresponding actions from the UK government to bolster its own medicine supply chains in response to these developments.
Sources
DW News
